| Prev Close | 186.92 |
| Open | 186.39 |
| Day Low/High | 184.75 / 187.40 |
| 52 Wk Low/High | 163.31 / 210.19 |
| Volume | 2.95M |
| Avg Volume | 2.98M |
Amgen Inc. (AMGN)
185.50
1.42
0.76
NASDAQ : Health Technology
| Exchange | NASDAQ |
| Shares Outstanding | 630.00M |
| Market Cap | 116.35B |
| EPS | 12.70 |
| P/E Ratio | 14.82 |
| Div & Yield | 5.80 (2.80%) |
Latest News
Apple Jumps After Reporting a Slight Earnings, Revenue Beat
Apple shares are up nearly 4% in after-hours trading.
Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
Jim Cramer: This Market Takes Its Cue From the Positive and Ignores the Negative
So far 2019 is proving to be a year where things have a habit of working out right.
Takeda Pharmaceutical CEO Talks Big Pharma Trends
One of pharma's biggest CEO's talks M&A action on the exchange.
Health Care Stocks Face Political Risk, How I'm Playing Netflix: Market Recon
Do we have to run for the hills? Not necessarily.
Amgen Is a Bright Spot in This Stock Market: Here's How to Play It
After the very negative market environment the past few months it is refreshing and exciting to find a stock with some upside potential.
Jim Cramer: Innovation Is on Display at the J.P. Morgan Healthcare Conference
We're out in San Francisco this week covering the amazing innovations that so many companies reveal at this annual conference.
Celgene Surges as Bristol-Myers Squibb Blockbuster Deal Begins Year With a Bang
Big pharma could be primed for an M&A Boom after Bristol-Myers Squibb's blockbuster deal for Celgene.
This 2019 Market Optimism Is Misplaced: Market Recon
Take upbeat outlooks for equities with a grain of salt, and try these sectors to stay safe.
The Real Money Post-Industrial Average Has Jumped 11% So Far This Year
For the month of November RMPIA climbed 1.2% month over month.
Pfizer Shares Jump on Monday After Company Signals Higher Price Push
Pfizer pushes higher on price increases.
Tech Selloff Could Work in Favor of Pharmaceutical Stocks
Pharma could be the best parking spot for your money if the market keeps trending downward.
Amgen Is Showing Independent Strength in a Bullish Sign for the Future
Investors should continue to hold Amgen.
Jim Cramer: Even Safe-Haven Big-Cap Drug Stocks Are Now Broken
Once the safest stocks in the book, the big-cap drug companies are now toxic.
Staying Long Apple Into Tuesday's Product Launch: Market Recon
My target price and panic points have changed, and I am watching for a chance to add or shave some off, depending on which direction the stock takes.
Here Are 9 Takeaways From Last Night's Meltdown: Market Recon
It becomes difficult for me to tell you where to run in these markets...
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Novice Trade: Amgen
Amgen calls just look too cheap to pass up here.
Jim Cramer: 5 Sectors to Buy on This 'Turkish Contagion' Market Drop
It is all about perception, and here are strong names to pick up on market weakness.
Biotechs: Adding to Radius Health, Flexion
This downward action in the small biotech sector tends to happen often in the 'dog days' of summer.
3 Best Ways to Play Amazon, Starbucks and Amgen After Earnings
Here are 3 ways to play these 3 stocks on earnings.
Charting 3 Big Names After Earnings
How to play Amazon, Starbucks and Amgen on earnings news.
Biotech Stocks Rally on Biogen's Landmark Test
Investors might be finally recognizing the hidden value of the firms' drug research and development.
Amgen Is Ready to Breakout on the Upside
Let's go to the charts.
Jim Cramer: Move Over FANG, Long Live INJFANG
The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.
Emboldened By Biotech Names
For the trade, I'm opting to use the iShares Nasdaq Biotechnology ETF.
When the Stock Is the Only Option
Options spreads aren't tradable with some small biotechs, making shares the only way to play.
Jim Cramer: Are Markets Getting Tired of Trump, Trade and Tariffs?
Sooner or later, bargain hunters will say: 'Enough already. It can't be that bad.'
